{"groups":[{"description":"RADIOIMMUNOTHERAPY: Patients receive a test dose of iodine I 131 tositumomab IV on day -24 to determine biodistribution. Patients then receive therapeutic iodine I 131 tositumomab IV over approximately 40-60 minutes on day -14 and are entered into radiation isolation until day -4.\n\nCHEMOTHERAPY: Patients receive etoposide IV on day -4 and cyclophosphamide IV on day -2.\n\nAUTOLOGOUS STEM CELL TRANSPLANTATION: Patients undergo autologous peripheral blood stem cell transplantation on day 0.\n\ncyclophosphamide: Given IV\n\netoposide: Given IV\n\niodine I 131 tositumomab: Given IV\n\nquality-of-life assessment: Ancillary study\n\nperipheral blood stem cell transplantation: Undergo ASCT given via central catheter","id":"FG000","title":"Treatment (Radio Labeled Monoclonal Antibody, Chemotherapy)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Eligibility requirement not met - HAMA+"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Rapid disease progression"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Eligibility requirement not met-low CD20"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"111"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"107"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}